ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Treatment of heart failure
Treatment of hyponatremia
Vasopressin V2 receptor antagonist
Benzamide, N-[4-[(7-chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-metylphenyl]-2-metyl- (USAN)
- Tolvaptanum (Latin)
- Tolvaptan (German)
- Tolvaptan (French)
- Tolvaptán (Spanish)
- Tolvaptan (OS: USAN, JAN, BAN)
- OPC-41061 (IS)
- UNII-21G72T1950 (IS)
Otsuka, Germany; Otsuka Pharmaceuticals Europe, United Kingdom
Korea Otsuka Pharmaceutical, South Korea; Otsuka, Canada; Otsuka, Germany; Otsuka, Denmark; Otsuka, Spain; Otsuka, Finland; Otsuka, France; Otsuka, Hong Kong; Otsuka, Netherlands; Otsuka, Portugal; Otsuka America Pharmaceuticals, United States; Otsuka Pharma Scandinavia, Sweden; Otsuka Pharmaceutical, Japan; Otsuka Pharmaceutical, Lithuania; Otsuka Pharmaceutical, Norway; Otsuka Pharmaceutical, Poland; Otsuka Pharmaceuticals Europe, United Kingdom; Otsuka-GB, Italy; Thai Otsuka, Thailand
|BAN||British Approved Name|
|IUPAC||International Union of Pure and Applied Chemistry|
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
|WHO||World Health Organization|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.